SONOROUS™
neurovascular

UPDATE TO SONOROUS NV INVESTORS
March 2024

Sonorous NV (SNV) is making great progress in developing BosStent to treat patients with symptomatic cerebral venous diseases associated with pulsatile tinnitus (PT).

Series A Common Stock Financing:

We closed our Series A common stock financing in 4 successive closings. The first on November 30, 2023 in the amount of $19.0MM. The second on December 31, 2023 in the amount of $10.5MM. The third on January 31, 2024 in the amount of $4.9MM. And a fourth and final close on February 26, 2024 in the amount of $2.8MM that will bring the Series A common stock closing to $37.2MM with a post money of $87.2MM. Total raised since inception in Q1 2022 is $42.9MM. I want to thank everyone for their patience with executing the documents and transferring funds. The cash on hand will be sufficient to conduct the USA IDE Pivotal Trial and achieve regulatory approval in both Europe in 2025 and USA in 2026 as well as to execute our global market launch.

Development Update:

The team has continued with development activities. SNV BosStent continues to be used to treat patients in Canada under the "Special Access Programme". SNV is expected to continue to treat patients in Canada throughout 2024. The team is active in completing the design and development processes for both BosStent and a novel delivery catheter. This includes in-vitro and in-vivo testing, intellectual property updating, regulatory planning for IDE trial enrollment. We are on track. In the next weeks I will send a more comprehensive update with respect to the milestones ahead of us for FDA IDE Pivotal Trial commencement and CE Marking Plan.

SNV team at NAMSA in Minneapolis January 29-30 conducting GLP study for BosStent. Pictured from left to right; Jake le, VP R&D, Waleed Brinjikji, MD, co-PI for IDE trial, Jill Munsinger, Regulatory Consultant, Vitor Mendes-Pereira, MD, SNV co-founder, Dave Ferrera, CEO and co-founder of SNV, Athos Patsalides, MD, co-PI for IDE Trial, Joel Harris, VP GM for SNV.

Clinical Update: New Health Canada Special Access Procedures.

Patients will continue to be treated with BosStent at St. Michael's Hospital in Toronto, Canada. 15 patients have been treated with BosStent since December 2022. Sonorous plans to continue treating patients in Canada through 2024 and until the commencement to the FDA IDE Study.

Below are two procedures performed the week of February 5, 2024 in Toronto, Ontario.

Patient 14 is a 30-year old female with a left sided stenosis of the transverse sinus. She had a 64% stenosis, which would qualify for our proposed IDE trial inclusion criteria for an intrinsic sinus stenosis. The normal vessels were 7mm. The BosStent implanted is an 8mm diameter x 45mm length. The patient awoke with "silence" and complete resolution of pulsatile tinnitus symptoms. She was discharged the next day.



Pre-treatment DSA 3D.



Post Stent CTA

Patient 15 is a middle-aged male. Not obese. He had a very significant right, sigmoid sinus stenosis and diverticulum. The diverticulum was approximately 5mm x 5mm. The degree of stenosis was a challenge to calculate, but was estimated at about 70%. The patient was treated with the 8mm x 45mm BosStent. The device opened well through the curve with excellent apposition. The patient awoke from surgery in PACU and reported that the pulsatile tinnitus was gone.



Pre-treatment DSA 3D



Post Stent DSA

Best,

Dave Ferrera

Chairman & CEO